yingweiwo

Tasquinimod (ABR-215050; TASQ)

Alias: ABR-215050; ABR215050; BR-215050; Tasquinimod [INN]; 4-Hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-(4-(trifluoromethyl)-phenyl)-1,2-dihydroquinoline-3-carboxamide; 756U07KN1R; ABR 215050
Cat No.:V0268 Purity: ≥98%
Tasquinimod (also known as ABR215050),aquinoline-3-carboxamide linomide analogue and an investigational drug, is a novel, and orally bioactive anti-angiogenic agent which potently inhibits HDAC4 allosterically with with potential anticancer activity.
Tasquinimod (ABR-215050; TASQ)
Tasquinimod (ABR-215050; TASQ) Chemical Structure CAS No.: 254964-60-8
Product category: HDAC
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
2mg
5mg
10mg
25mg
50mg
100mg
250mg
500mg
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Tasquinimod (also known as ABR215050), a quinoline-3-carboxamide linomide analogue and an investigational drug, is a novel, and orally bioactive anti-angiogenic agent which potently inhibits HDAC4 allosterically with with potential anticancer activity. For the treatment of castration-resistant prostate cancer, Tasquinimod is presently being investigated in Phase 3 clinical trials.

Biological Activity I Assay Protocols (From Reference)
Targets
HDAC4 ( Kd = 10-30 nM )
ln Vitro

Tasquinimod blocks the growth of new tumors by inhibiting the deacetylation of HIF-1α that is dependent on HDAC4/N-CoR/HDAC3.[1]
Tasquinimod also targets myeloid cells that have infiltrated the body. By preventing S100A9 from interacting with its ligand receptor, advanced glycation end products, and Toll-like receptor 4, it modifies local tumor immunity.[3]

ln Vivo
Through this mechanism, tasquinimod is effective as a monotherapeutic agent against human prostate, breast, bladder, and colon tumor xenografts, where its efficacy could be further enhanced in combination with a targeted thapsigargin prodrug (G202) that selectively kills tumor endothelial cells. Together, our findings define a mechanism of action of tasquinimod and offer a perspective on how its clinical activity might be leveraged in combination with other drugs that target the tumor microenvironment.[1]
Based upon its superior potency (i.e., 30- to 60-fold more potent than linomide) in these assays and its lack of a proinflammation in the Beagle-dog, ABR-215050 (tasquinimod), Figure 1, was characterized for dose-response ability to inhibit the growth of a series of four additional human and rodent prostate cancer models in mice. Pharmacokinetic analysis following oral dosing documented that blood and tumor tissue levels of ABR-215050 as low as 0.5-1 microM are therapeutically effective. This efficacy is correlated with inhibition of angiogenesis in a variety of assays (endothelial capillary tube formation, aortic ring assay, chorioallantoic membrane assay, real-time tumor blood flow and PO(2) measurements, tumor blood vessel density, and tumor hypoxic and apoptotic fractions). Conclusions: Based upon its robust and consistent anti-angiogenic activity and thus tumor growth, ABR-215050 has entered clinical trials for the treatment of prostate cancer.[2]
When nude mice bearing CWR-22RH human prostate tumors were treated with oral tasquinimod, there was a profound growth inhibition, associated with an up-regulation of TSP1 and a down- regulation of HIF-1 alpha protein, androgen receptor protein (AR) and glucose transporter-1 protein within the tumor tissue. Changes in TSP1 expression were paralleled by an anti-angiogenic response, as documented by decreased or unchanged tumor tissue levels of VEGF (a HIF-1 alpha down stream target) in the tumors from tasquinimod treated mice. Conclusions: We conclude that tasquinimod-induced up-regulation of TSP1 is part of a mechanism involving down-regulation of HIF1alpha and VEGF, which in turn leads to reduced angiogenesis via inhibition of the "angiogenic switch", that could explain tasquinimods therapeutic potential.[3]
Tasquinimod (30 mg/kg/d p.o.) inhibits tumor growth in mice expressing human and rodent prostate cancer models by exhibiting anti-angiogenic activity. [2]
Enzyme Assay
Tasquinimod has a Kd of 10–30 nM for binding to the regulatory Zn2+ binding domain of HDAC4.Total HDAC and isotype specific HDAC enzymatic activity was assayed on a per cell basis using the appropriate substrates as described previously. Recombinant human HDAC isotypes were obtained commercially. These experiments were repeated a minimum of 3 independent times with 5 replicates per time point.[1]
Surface plasmon resonance[1]
SPR analysis was carried out with the Biacore 3000 system as described previously. Sensor chips, amine coupling kit, immobilization and running buffers, and regeneration solutions were as described previously. Binding to Tasquinimod was determined for human full length N-terminal GST-tagged HDAC4. GST-tagged HDAC4 was immobilized onto a CM5 chip through an amine-linkage. This chip was used to determine binding of full length human N-CoR. These experiments were repeated 3 independent times.
Cell Assay
CWR-22RH and LNCaP (ATCC) are two human prostate cancer cell lines that express PSA and have a mutated androgen receptor. Despite being androgen independent, they both show sensitivity to androgen stimulation of growth. The in vitro exposure of hormone-independent cell lines LNCaP19 and DU145 to Tasquinimod (0.1-100 μM) is followed by an assessment of TSP1 induction. While LNCAP19 is cultivated in RPMI-medium with 10% hormone free (RDCC) FCS, CWR-22RH, LNCaP, and DU145 are grown in RPMI Medium 1640 containing 10% FCS and L-Glutamine mixture.
Animal Protocol
Nude BALB/c mice were used for subcutaneous implantation of human prostate tumor cells LNCaP and CWR-22RH. All animal experiments were conducted in accordance with the Bioethics Committee guidelines in Lund, Sweden. Tumor growth was measured with a microcaliper twice a week throughout the experiment, and the final tumor burden was measured by weight on the day of termination of the experiment. Distribution of tasquinimod at 1 mg/kg/day and 10 mg/kg/day (administered orally via the drinking water) started on day 7 after inoculation.[4]
Tumor bearing mice (LNCaP inoculated in nude mice) were treated with tasquinimod at 10 mg/kg (ad.lib.) and the tumors of each of the 2 different treatment groups were excised after 24 h of treatment (start day 14 or day 21 after inoculation) and total RNA was isolated.[4]
Therefore, linomide analogs and tasquinimod were initially screened to determine their in vivo potency to inhibit growth of the Dunning R-3327 AT-1 rat prostate cancer model in rats and their potency to inhibit angiogenesis in a Matrigel assay in mice.[2]
Mice: The LNCaP and CWR-22RH human prostate tumor cells are subcutaneously implanted into naked BALB/c mice. For the duration of the experiment, tumor growth is measured twice a week using a microcaliper, and on the day of experiment termination, the final tumor burden is determined by weight. After the inoculation, Tasquinimod was first distributed orally on day seven at doses of 1 mg/kg and 10 mg/kg per day (given through drinking water).
ADME/Pharmacokinetics
Tasquinimod has been found to have a low clearance of 0.19 L/h at 0.5 mg and 0.22 L/h at 1 mg dose level, making increase in systemic exposure lesser than the dose increase. The volume of distribution is 5.9 L, the elimination half-life is 40±16 hours, and the maximum plasma concentrations occur at 2.6 hours. Area under the curve steady state amounts to 4.8 μmol/h. Co-administration with food has not been found to affect the pharmacokinetic properties of tasquinimod. No relationship between pharmacokinetic parameters and race, ethnicity, or hepatic function has been identified. https://www.tandfonline.com/doi/full/10.2147/OTT.S53524#d1e353
Toxicity/Toxicokinetics
Tasquinimod, an S100A9 inhibitor, is well tolerated in pts with RRMM as a single-agent and in combination with IRd, with a single-agent MTD of 1 mg daily after a 1-week dose escalation. ;
References

[1]. Cancer Res . 2013 Feb 15;73(4):1386-99.

[2]. Prostate . 2006 Dec 1;66(16):1768-78.

[3]. Cancer Chemother Pharmacol . 2014 Jan;73(1):1-8.

[4]. Mol Cancer . 2010 May 17:9:107.

Additional Infomation
Tasquinimod is a quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer involving human prostate cancer xenografts.
The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts
Tasquinimod is a quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer involving human prostate cancer xenografts.
Drug Indication
Investigated for use/treatment in prostate cancer.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C20H17F3N2O
Molecular Weight
406.36
Exact Mass
406.114
Elemental Analysis
C, 59.11; H, 4.22; F, 14.03; N, 6.89; O, 15.75.
CAS #
254964-60-8
Related CAS #
254964-60-8
PubChem CID
54682876
Appearance
White to light yellow solid powder
Density
1.4±0.1 g/cm3
Boiling Point
501.5±50.0 °C at 760 mmHg
Flash Point
257.1±30.1 °C
Vapour Pressure
0.0±1.4 mmHg at 25°C
Index of Refraction
1.606
LogP
2.63
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
7
Rotatable Bond Count
3
Heavy Atom Count
29
Complexity
686
Defined Atom Stereocenter Count
0
SMILES
FC(C1C([H])=C([H])C(=C([H])C=1[H])N(C([H])([H])[H])C(C1C(N(C([H])([H])[H])C2C([H])=C([H])C([H])=C(C=2C=1O[H])OC([H])([H])[H])=O)=O)(F)F
InChi Key
ONDYALNGTUAJDX-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3
Chemical Name
4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]quinoline-3-carboxamide
Synonyms
ABR-215050; ABR215050; BR-215050; Tasquinimod [INN]; 4-Hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-(4-(trifluoromethyl)-phenyl)-1,2-dihydroquinoline-3-carboxamide; 756U07KN1R; ABR 215050
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~81 mg/mL (~199.3 mM)
Water: <1 mg/mL
Ethanol: ~11 mg/mL warmed (~27.1 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (6.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 2.5 mg/mL (6.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


Solubility in Formulation 4: ≥ 2.5 mg/mL (6.15 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 5: ≥ 2.5 mg/mL (6.15 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

Solubility in Formulation 6: 5% DMSO+30% PEG 300+ddH2O: 8mg/mL

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.4609 mL 12.3044 mL 24.6087 mL
5 mM 0.4922 mL 2.4609 mL 4.9217 mL
10 mM 0.2461 mL 1.2304 mL 2.4609 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04405167 Recruiting Drug: Tasquinimod
Drug: IRd chemotherapy
Multiple Myeloma University of Pennsylvania July 10, 2020 Phase 1
NCT01234311 Completed Drug: tasquinimod
Drug: Placebo
Prostate Cancer Active Biotech AB March 2011 Phase 3
NCT01048203 Completed Drug: ABR-215050 Healthy Active Biotech AB January 2009 Phase 1
NCT01513733 Completed Drug: tasquinimod Prostate Cancer Andrew J. Armstrong, MD January 2012 Phase 1
NCT02159950 Completed Drug: Tasquinimod
Biological: Sipuleucel-T
Metastatic Prostate Carcinoma
Stage IV Prostate Cancer
Roswell Park Cancer Institute January 2015 Phase 2
Biological Data
  • Tasquinimod

    A. Chemical structure of tasquinimod (TasQ) B. Comparison of anti-cancer efficacy of tasquinimod against CWR22-RH human prostate cancer xenografts.Cancer Res.2013 Feb 15;73(4):1386-99.
  • Tasquinimod

    A. Tas-Q (1µM) and TSA (200nM) prevent lysine deacetylation in H3-histone at position 9 &19 induced by hypoxia in all of the human prostate cancer lines tested. β-actin was used as a loading control. B. Western blots of indicated HDAC in normal human prostate epithelial (i.e., 957E/hTERT) cells and LNCaP, PC-3, and DU-145 human PCs.Cancer Res.2013 Feb 15;73(4):1386-99.
  • Tasquinimod

    A. HDAC4 increases and 1µM TasQ decreases HIF-1α protein in HEK-293T cells. β-actin was used as a loading control. B. TasQ lowers level of HDAC4 in the nuclei of LNCaPs in both normoxia and hypoxia.Cancer Res.2013 Feb 15;73(4):1386-99.
Contact Us